Journal
JOURNAL OF NEUROCHEMISTRY
Volume 106, Issue 3, Pages 1225-1236Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1471-4159.2008.05471.x
Keywords
Alzheimer's disease; amyloid; glutamine cyclotransferase; glutaminyl cyclase; pyroglutamic acid
Categories
Ask authors/readers for more resources
Modified amyloid beta (A beta) peptides represent major constituents of the amyloid deposits in Alzheimer's disease and Down's syndrome. In particular, N-terminal pyroglutamate (pGlu) following truncation renders A beta more stable, increases hydrophobicity and the aggregation velocity. Recent evidence based on in vitro studies suggests that the cyclization of glutamic acid, leading to pGlu-A beta, is catalyzed by the enzyme glutaminyl cyclase (QC) following limited proteolysis of A beta at the N-terminus. Here, we studied the pGlu-formation by rat QC in vitro as well as after microinjection of A beta(1-40) and A beta(3-40) into the rat cortex in vivo/in situ with and without pharmacological QC inhibition. Significant pGlu-A beta formation was observed following injection of A beta(3-40) after 24 h, indicating a catalyzed process. The generation of pGlu-A beta from A beta(3-40) was significantly inhibited by intracortical microinjection of a QC inhibitor. The study provides first evidence that generation of pGlu-A beta is a QC-catalyzed process in vivo. The approach per se offers a strategy for a rapid evaluation of compounds targeting a reduction of pGlu formation at the N-terminus of amyloid peptides.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available